

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.
Investor Presentation Deck


Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.
Investor Presentation Deck
VANCOUVER, Washington, Jan. 13, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]
– Strengthens Company’s portfolio with the manufacturers of leading high-quality, crafted cannabis edibles and extracts – Continues to establish itself as a vertically integrated operator with the latest acquisition announcement – Gains access in close […]
Medicine Man Technologies, Inc. (OTC: MDCL) CEO Interview with Andy Williams. NEXT SUPER STOCK conference presenter, Andy Williams delivers an update on MDCL’s transformation into a vertically […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
